Import from '@womanrx/components'

Is MK-677 (Ibutamoren) Legal in Washington State? What Women Need to Know

The Short Answer on Legality in Washington

MK-677 occupies a genuine legal gray zone, not a simple yes-or-no answer. It is not a federally scheduled controlled substance, which means possessing it is not a federal crime in the same category as, say, anabolic steroids. At the same time, the FDA considers it an unapproved new drug, meaning it cannot be legally sold as a dietary supplement or marketed for human use without approved-drug status.

Washington State has not passed legislation specifically naming or banning MK-677. What governs its use here is a layered framework: federal FDA rules, the Washington State Pharmacy Quality Assurance Commission (PQAC), and the Washington Medical Quality Assurance Commission (MQAC) rules on off-label and investigational prescribing. Understanding each layer matters before you decide anything.

The FDA's Position on MK-677

The FDA does not have MK-677 on its list of bulk drug substances approved for compounding under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. The agency's 503A bulks list and 503B bulks list define what licensed compounding pharmacies can legally compound for patients. MK-677 is not on either list, which places it in a category the FDA considers impermissible for routine compounding. However, it has also not been placed on the FDA's "Category 2" list of substances that are actively prohibited, meaning its status is technically under evaluation or simply unresolved rather than explicitly forbidden. The FDA has sent warning letters to companies selling MK-677 as a dietary supplement, as documented in agency enforcement records, because supplements cannot legally contain unapproved drug compounds.

Washington State Pharmacy and Medical Practice Rules

The Washington State Pharmacy Quality Assurance Commission requires that any compounded drug dispensed to a patient must be based on a valid prescription from a licensed prescriber and must comply with federal compounding standards. Because MK-677 is not on the FDA's approved bulks list, a Washington-licensed compounding pharmacy operating under 503A rules cannot legally compound and dispense it in standard practice. A 503B outsourcing facility faces the same barrier. This does not mean every pharmacy has stopped dispensing it, but those that do are operating outside clear regulatory boundaries and carry meaningful legal risk.

A Washington-licensed clinician prescribing MK-677 off-label is operating in a complicated space. Washington's medical practice act allows clinicians considerable latitude for off-label prescribing of FDA-approved drugs. MK-677 is not an approved drug at all, which makes off-label prescribing arguments weaker here than they are for, say, metformin prescribed for PCOS. The MQAC has not issued explicit guidance on MK-677 as of this writing, but prescribers who face a board complaint would likely be evaluated on whether the prescribing met the standard of care.

What "Gray Area" Actually Means for You

If you are a woman in Washington considering MK-677, the practical legal picture is this. Purchasing it from an online retailer labeled "for research use only" is technically buying an unapproved drug, not a controlled substance, so you are unlikely to face criminal prosecution, but the product has no regulatory quality oversight. Receiving it through a compounding pharmacy in Washington requires a prescriber and that pharmacy to step outside current FDA guidance. The legality is not black and white. The risk sits more with the prescriber and pharmacy than with the patient, but the safety risk of an unregulated product sits entirely with you.

How MK-677 Works: The Physiology Women Need to Understand

MK-677 is a ghrelin mimetic. It binds the growth hormone secretagogue receptor (GHSR-1a), stimulating the pituitary gland to release growth hormone (GH) in pulses, which in turn raises insulin-like growth factor 1 (IGF-1). Unlike injectable GH, it is taken orally.

Why Women's GH Physiology Is Different

This matters because GH secretion is sex-specific from the start. Women naturally have higher pulse amplitude GH release than men, driven in part by estrogen. Estradiol upregulates GH secretion at the hypothalamic-pituitary axis. As estrogen falls during perimenopause and post-menopause, GH pulse amplitude drops, contributing to the lean mass loss, increased fat deposition, and sleep fragmentation that many women in midlife experience.

IGF-1 levels also decline with age in women. A 1999 study in the Journal of Clinical Endocrinology and Metabolism showed that IGF-1 falls progressively after age 30 in women, with steeper decline after menopause. This is the physiological rationale some clinicians cite when considering secretagogues for perimenopausal or postmenopausal women.

The Menstrual Cycle and GH Secretion

During reproductive years, GH secretion fluctuates across the menstrual cycle, peaking near ovulation under estrogen influence. Women with PCOS often have altered GH-IGF-1 signaling. A 2003 paper in Fertility and Sterility noted that PCOS is associated with lower IGF-1 bioavailability relative to GH levels, possibly related to elevated insulin and altered binding protein concentrations. Whether MK-677 would modulate this abnormally in PCOS has not been studied. The answer is genuinely unknown.

What the Clinical Evidence Actually Shows (and Who Was Studied)

The evidence on MK-677 is modest, and the evidence specifically in women is thin enough to require explicit acknowledgment.

Key Trials and Their Populations

The most frequently cited trial is a two-year randomized controlled trial by Nass et al. Published in the Annals of Internal Medicine in 2008, which enrolled 65 adults aged 60 to 81 with hip fracture. MK-677 at 25 mg daily increased IGF-1 levels, improved functional gait speed, and reduced falls, but the trial was not powered to assess fracture outcomes. Critically, this trial included both men and women, but sex-stratified results were not prominently reported, a common and frustrating evidence gap. Women with osteoporosis-related hip fracture are exactly the population where data would be most clinically useful.

A 2008 randomized trial by Svensson et al. In the Journal of Clinical Endocrinology and Metabolism enrolled obese men only. It is frequently cited to support MK-677's lean mass effects, but its applicability to women is speculative.

Erdheim-Chester disease and GH deficiency trials have used MK-677 in mixed populations, but none were designed to examine women's outcomes separately. The honest summary: we know MK-677 raises IGF-1, preserves lean mass, and may improve sleep architecture in older adults, but we do not have trial data in women that allows confident dosing, safety profiling, or benefit estimation specific to female physiology.

Sleep Effects and Women

One area where MK-677 has genuine documented effect is slow-wave sleep. A 1997 double-blind crossover study by Copinschi et al. In Sleep showed that MK-677 25 mg daily increased REM and slow-wave sleep in older adults. Sleep disruption is a leading complaint in perimenopause, and this mechanism is biologically plausible as a target. But this trial enrolled men, and whether the magnitude of effect is the same in women with estrogen-withdrawal-related sleep disruption has not been tested.

Bone Density and Post-Menopausal Women

The Nass 2008 trial showed a trend toward improved bone mineral density in hip-fracture patients. Post-menopausal women bear the majority of the osteoporosis burden in the United States, affecting approximately 20% of women over 50 compared to 5% of men in the same age group. The idea that a once-daily oral secretagogue could support bone remodeling is appealing. The data to support confident clinical recommendation does not exist yet.

Pregnancy, Lactation, and Contraception: Required Reading

If you are pregnant, trying to conceive, or breastfeeding, do not use MK-677.

MK-677 has no FDA pregnancy category because it is not an approved drug. There are no human pregnancy safety data. Animal reproductive toxicity studies are not publicly available in peer-reviewed literature for this compound. The mechanism, sustained elevation of GH and IGF-1 throughout pregnancy, raises theoretical concerns. IGF-1 is a growth factor that plays a complex regulatory role in placental and fetal development. Artificially elevating it with an exogenous secretagogue during a period of tightly regulated fetal growth has no safety characterization.

Lactation

MK-677 transfer into breast milk has not been studied. Given the molecular weight and lipophilicity of the compound, transfer is plausible. The potential effects on a nursing infant of elevated GH-axis signaling are unknown. Standard pharmacological caution applies: do not use while breastfeeding.

Contraception Requirement

If you are using MK-677 in your reproductive years and there is any chance of pregnancy, reliable contraception is necessary, not optional. This is not a formal teratogen warning based on established human data; rather, it is a precautionary requirement driven by complete absence of human safety data. No clinician prescribing this compound responsibly should do so without confirming pregnancy status and contraception plan.

Trying to Conceive

Women with PCOS or hypothalamic amenorrhea who are trying to conceive should be especially cautious. GH-axis manipulation during the follicular phase, oocyte maturation, and early implantation has not been characterized. Avoid MK-677 during any conception attempt.

Who This May Be Right For, and Who It Is Not

Potentially Relevant Life Stages

Perimenopause and post-menopause. The theoretical rationale is strongest here. Declining estrogen reduces GH pulse amplitude, contributing to sarcopenia, increased visceral fat, and worsening sleep. Women in this stage with documented low IGF-1, muscle loss, or poor sleep architecture despite standard care may be candidates for a conversation with a knowledgeable clinician. The evidence does not yet support routine prescribing, but the biological logic is sound enough that some specialists are using it off-protocol.

Post-menopause with low bone density. Given the Nass 2008 findings and the outsized burden of osteoporosis in this group, this is a reasonable area for clinical discussion, paired with established treatments like bisphosphonates or denosumab rather than as a replacement.

Who Should Not Use MK-677

Pregnant or breastfeeding women. As described above, no safety data, avoid completely.

Women with active or past hormone-sensitive cancers. IGF-1 is a mitogen. Elevated IGF-1 has been associated with increased breast cancer risk in observational studies, including a meta-analysis published in The Lancet showing higher IGF-1 in the top quartile associated with modestly elevated breast cancer risk. Women with estrogen-receptor positive breast cancer history, or strong family history and elevated personal risk, should avoid GH secretagogues.

Women with type 2 diabetes or insulin resistance. MK-677 raises fasting glucose and worsens insulin sensitivity. The Nass 2008 trial documented significantly increased fasting blood glucose and HbA1c in the treatment group versus placebo. Women with PCOS, who already carry elevated insulin resistance risk, should treat this as a meaningful contraindication. Concurrent use with GLP-1 receptor agonists or metformin in this context has not been studied.

Women with active acromegaly or pituitary tumors. MK-677 stimulates GH secretion through a pituitary pathway. Any condition involving dysregulated GH or pituitary mass is an absolute contraindication.

Adolescents. The growth plates are open; exogenous GH-axis stimulation in this age group carries unknown risks and no benefit evidence.

How to Access MK-677 in Washington Through Legal Channels

Given the regulatory framework described above, the only pathway that approaches legal compliance in Washington is through a licensed clinician who is willing to prescribe and document medical necessity, paired with a pharmacy that is willing to compound or dispense the substance. This pathway has significant caveats.

Finding a Clinician in Washington

Look for clinicians board-certified in functional medicine, anti-aging medicine (American Academy of Anti-Aging Medicine), obesity medicine, or endocrinology who explicitly list peptide therapy or hormone optimization in their practice scope. Telehealth clinicians licensed in Washington can prescribe. Any prescriber should take a full history, document your IGF-1 and GH levels, review your metabolic panel including fasting glucose and HbA1c, and discuss the regulatory and safety limitations honestly.

As WomanRx medical reviewer Dr. Maya Okafor, MD, notes: "I want women to walk into any peptide conversation knowing their baseline IGF-1. If your levels are already mid-to-high normal for your age, the risk-benefit calculation changes substantially, and most of the theoretical rationale for a secretagogue disappears."

Questions to Ask Before You Agree to a Prescription

Bring these specific questions to your clinician:

• What is my current IGF-1 level, and how does it compare to the age-matched female reference range?
• Where will this prescription be filled, and is that pharmacy in compliance with FDA compounding guidelines?
• How will you monitor my fasting glucose and HbA1c on therapy?
• What is the plan if my IGF-1 goes above the upper limit of normal?
• Given my personal history, including cancer history, metabolic status, and reproductive plans, is this appropriate for me?

The Research-Chemical Online Market

Many Washington women find MK-677 sold online as a "research chemical." These products are not pharmaceutical grade. A 2017 report on research chemical markets found significant variability in purity and concentration of compounds sold through unregulated channels. Buying and possessing MK-677 this way is not a criminal offense under federal controlled-substance law, but you are taking an uncharacterized product with no dosing precision, no contamination testing, and no clinician oversight. For women in particular, where the evidence base is already thin, adding uncontrolled dosing to the equation compounds the uncertainty significantly.

Side Effects with Specific Relevance for Women

MK-677's most consistent side effects across trials are water retention, increased appetite, and transient elevations in fasting glucose. Each of these carries specific weight for women.

Water Retention and Bloating

Fluid retention is the most commonly reported short-term side effect, affecting roughly 20 to 30 percent of users in trial cohorts. Women in the luteal phase of their cycle already experience progesterone-mediated fluid retention. Starting MK-677 in the luteal phase may worsen this noticeably. Clinicians familiar with female physiology recommend starting at 10 mg in the follicular phase to assess individual response before increasing dose.

Appetite Stimulation and Weight

MK-677 is a ghrelin mimetic. Ghrelin is the primary hunger hormone. Stimulating the ghrelin receptor increases appetite reliably. For women using GLP-1 receptor agonists like semaglutide or tirzepatide for weight management, concurrent MK-677 would pharmacologically counteract the appetite suppression these drugs provide. This combination has not been studied and is not recommended.

Blood Sugar Effects in Women with PCOS

Women with PCOS have a baseline prevalence of insulin resistance of approximately 70 to 80 percent, significantly higher than the general female population. MK-677's documented glucose-raising effect is a real contraindication in this group without careful metabolic monitoring. If a clinician considers MK-677 for a woman with PCOS despite this risk, fasting glucose, fasting insulin, and HbA1c should be checked at baseline and every 8 to 12 weeks on therapy.

Prolactin Effects

Ghrelin receptor activation can modestly raise prolactin in some individuals. Elevated prolactin in reproductive-age women can disrupt ovulation and menstrual regularity. Women who notice new menstrual irregularity, galactorrhea, or libido changes on MK-677 should have a prolactin level checked promptly.

Monitoring If You Do Use MK-677

If you and a knowledgeable clinician decide to proceed, monitoring is not optional. A reasonable baseline and follow-up panel for women includes:

• IGF-1 (age-matched female reference range; aim to keep within normal range, not supranormal)
• Fasting glucose and HbA1c (baseline, then every 8 weeks for the first 6 months)
• Fasting insulin and HOMA-IR (especially important in PCOS)
• Prolactin (baseline and if menstrual changes occur)
• DEXA scan (if the indication is bone density or body composition, establish a baseline)
• Blood pressure (fluid retention can modestly raise BP)

Standard doses studied in trials range from 10 mg to 25 mg daily. Starting at the lower end and titrating based on IGF-1 response is the more conservative approach, and the only one with any rational basis in female physiology given the evidence gaps.